New Delhi: Ahmedabad-based Zydus Group has entered into an in-licensing agreement with Switzerland-based Neovii to launch Grafalon, an immunosuppressant used in solid organ transplants and stem cell transplant, in India.
"The Zydus group will market this therapy through Zydus Trans-immune, a division that offers a range of therapies related to transplant medicine," group firm Cadila Healthcare said in a filing to the BSE.
Grafalon offers a specific advantage of efficacy and better safety profile through targeted immunosuppression, it added.
"More than 200,000 patients till date, in over 50 countries, have been treated with Grafalon," Cadila Healthcare said.
Transplant outcomes can be improved significantly by the use of immunosuppressant drugs like Grafalon, it added.
"Currently, an estimated 10,000 solid organ transplant and stem cell transplants are taking place annually across 200 plus transplant centres in India," the company said.
Shares in Cadila Healthcare, on Thursday, ended 0.36 per cent lower at Rs 387.20 apiece on the BSE, whose benchmark Sensex index finished down 0.41 per cent.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
